secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001854270-24-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024
---------------------------------------------------------------------------

- Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.
- Net loss $12.1M ($0.26 per share); R&D expenses rose to $8.8M from $7.1M on manufacturing costs.
- SENTI-202 Phase 1 trial for AML on track to dose first patient in Q2 2024; initial efficacy data by year-end 2024.
- Pilot trial of SENTI-301A for HCC in China (Celest partnership) expects first patient dosing in Q2 2024.
- Presented three abstracts at ASGCT 2024, including novel CAR discovery and engineered synthetic switches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/0001854270-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/snti-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer